MedTrace Logo

Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab

NCT01432223 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2015-04-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy in terms of the pathological complete response (pCR) rate and the efficacy to preoperative administration of Anthracycline-based regimen followed by Nab-paclitaxel and Trastuzumab in patients with HER2 positive operable breast cancer.

Conditions

  • Breast Cancer
  • HER-2 Positive Breast Cancer
  • Effects of Chemotherapy

Interventions

DRUG

Nab-paclitaxel

Nab-paclitaxel 260mg/m2 q3w

Sponsors & Collaborators

  • Osaka Medical College

    lead OTHER

Principal Investigators

  • Mitsuhiko Iwamoto, MD, PhD · Osaka Medical College

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-11-30
Completion
2014-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01432223 on ClinicalTrials.gov